Eli Lilly & Co. (LLY)
984.00
-19.57
(-1.95%)
USD |
NYSE |
Mar 05, 09:49
Eli Lilly Cash from Investing (Quarterly) : -2.802B for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Amgen, Inc. | -693.00M |
| Regeneron Pharmaceuticals, Inc. | 220.30M |
| Viking Therapeutics, Inc. | 75.61M |
| Arcellx, Inc. | 57.80M |
| Moderna, Inc. | -48.00M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 3.225B |
| Cash from Financing (Quarterly) | -2.879B |
| Free Cash Flow | 5.964B |
| Free Cash Flow Per Share (Quarterly) | 0.2691 |
| Free Cash Flow to Equity (Quarterly) | -1.104B |
| Free Cash Flow to Firm (Quarterly) | 352.96M |
| Free Cash Flow Yield | 0.67% |